Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients.

Penel, N; Cordoba, A; Mathoulin-Pelissier, S

Penel, N; Cordoba, A; Mathoulin-Pelissier, S.

Affiliation

Penel N; Direction of Clinical Research and Innovation, Centre Oscar Lambret, Lille 2; General Oncology Department, Centre Oscar Lambret, Lille. Electronic address: n-penel@o-lambret.fr.
Cordoba A; Radiation Therapy Department, Medical School, Centre Oscar Lambret, Lille.
Mathoulin-Pelissier S; Clinical Research and Clinical Epidemiology Unit, Department of Clinical Research and Medical Information, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01, Bordeaux; Team EPICENE, University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France.

Ann Oncol ; 28(11): 2891-2893, 2017 11 01.

Article in En | MEDLINE | ID: mdl-28945913

Subject(s)

Sarcoma/therapy; Soft Tissue Neoplasms/therapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Humans; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google